Introduction
Allogeneic hematopoietic cell transplantation (HCT) is a curative modality for patients with various malignant and non-malignant hematopoietic diseases. Recently, to reduce late toxicities from total body γ-irradiation (TBI) while increasing specificity and efficacy, monoclonal antibodies (MAb) labeled with β-emitting radionuclides, such as 131 I-labeled anti-CD45 MAb, have been investigated (1) (2) (3) (4) . However, β-emitting radionuclides are not optimal for killing the targeted hematopoietic cells due to their long path length and low dose rates (5) (6) (7) (8) . Owing to the long β-particle path (i.e. mean range 0.4 to 5 mm (9)) the majority of the emitted energy is deposited outside of the targeted hematopoietic cells. Thus, while specific targeting of hematopoietic cells may be achieved with the MAb, the β-particles may deliver non-lethal doses to the targeted cells while causing non-specific toxicity to surrounding normal tissues.
In contrast to β-emissions, α-particles are characterized by very high linear energy transfer, with most of the particles' energy being deposited over only a few cell diameters (i.e. 40-90 μm).
Given this favorable feature, we investigated bismuth-213 ( ) is an alternative α-particle-emitting radionuclide for radioimmunotherapy (13) . 211 At has a longer half-life than Bi. The antibody, a rat anti-murine CD45 MAb, 30F11 (2, 14) used in the mouse provided a model for understanding differences between the two radionuclides.
Materials and Methods
Antibody and Chemicals. The rat anti-murine CD45 MAb, 30F11, is an IgG 2b MAb that recognizes all murine CD45 isoforms (2) . The 30F11 hybridoma cell line was a gift from Dr. Irv maleimidopropionamide (referred to as ADTM) was prepared as previously described (15) .
Radionuclides.

213
Bi was obtained by elution from an 225 Ac generator purchased from the US Department of Energy (Oak Ridge, TN) as previously described (10). At was removed from irradiated bismuth targets by dry distillation and isolated in 0.05 N NaOH as previously described (16).
-5 - Bi was achieved by conjugation of IB-CHX-A´´ with 30F11 in 50 mM HEPES buffer, pH 8.5, at room temperature for 18 h as previously described (10) . Rigorous demetallation was conducted before conjugation with the MAb and again after the MAb-conjugate was purified. Modification of 30F11 for labeling with 211 At was achieved by treatment with 10 mM dithiotreitol (DTT) for 1 hour at room temperature, followed by buffer exchange into 20 mM sodium phosphate at pH 6.5, containing 1 mM EDTA, then addition of 10 equivalents of ADTM in DMSO to the DTT-treated 30F11 with ADTM. After the conjugation reaction proceeded for 1 hour at room temperature, the reaction mixture was eluted on a PD-10 column (Sephadex G-25) pre-equilibrated in PBS, pH and 24 h after injection, when 9%, 25%, 49% and 90% of the radionuclide had decayed.
For evaluation of tissue concentrations of radioactivity, eight tissues were examined, including muscle, lung, kidney, spleen, liver, intestine, neck and stomach. The spleen was used as a surrogate tissue for hematopoiesis as total organ weight could be serially followed in addition to tissue concentrations of radioactivity. Bone marrows were sent for pathological examination only. Blood samples were obtained by heart puncture immediately after sacrificing the mice. Excised tissues were blotted free of blood and weighed. The total blood volume was -7 -estimated to be 6% of body weight (17 At in mouse tissues using standard methods for α-particle and beta (electron) dosimetry.
Using the mathematical formalism established by the Medical Internal Radiation Dose (MIRD)
Committee of the Society of Nuclear Medicine (18), the absorbed doses (cGy) to target tissues for α-particles and electrons or β-particles were calculated from the available nuclear decay data (19) and biodistribution data (see Supplemental Information). The time-integrated activity (or total number of disintegrations) in each tissue was determined for each radionuclide by plotting the activity-time curve, identifying an appropriate function to represent the plotted data (by least-squares linear regression analysis), and by integrating the best-fit regression curve from time 0 to infinity. The radiation absorbed doses were then calculated using the MIRD -8 - At taking into account the 9.49x half-life factor between the two isotopes. Hepatic toxicity. The normal ranges [mean ± 2 SD] for AST, ALT, and total Bil were 129 ± 96 (U/L), 52 ± 31 (U/L) and 0.48 ± 0.27 (mg/dl), respectively, in an untreated cohort of mice.
Severe but non-lethal hepatic toxicity was observed at 3 hr after injection of 50 μCi At ( Figure 3B ).
Tissue pathology.
Mice in all experimental study groups gained weight over the study period, except the group receiving 20 μCi
211
At on 40 μg of MAb. In the group receiving 10 μCi
At, the bone marrow demonstrated progressive hypocellularity, and hematopoiesis significantly decreased at 24 h and 48 h after injection ( Figure 4A ). However, hematopoietic recovery occurred by 1 week after injection. Similarly, red pulp in the spleen significantly decreased and white pulp in the spleen became atrophic at 24 h and 48 h after injection ( Figure 4B ). In the 24 h sample, there was diffuse necrosis of lymphoid cells intermixed with proliferating lymphocytes. The white pulp became atrophic (approximately 25% of normal cellularity) and red pulp was depleted down to about 50% of normal cellularity at 24 h.
Megakaryocytes remained. However, recovery of hematopoiesis in the spleen was also observed in the specimen 1 week after injection. There were no pathological abnormalities in the liver or kidney.
Necropsies were performed on mice that received 20 μCi At, documenting protracted myelosuppression ( Figure 4C , row a). At day 11-12, the red and white pulps of the spleen were depleted down to 25% of normal cellularity and megakaryocytes almost disappeared in the groups receiving 20
At. In the groups receiving 50 μCi 211 At, the red and white pulps were depleted down to 5-10% of normal cellularity and megakaryocytes were rarely observed ( Figure 4C, row b) . There was no evidence of extramedullary hematopoiesis in the liver.
Discussion
The current study demonstrated that 211 At was more effective than Bi-labeled pan-hematopoietic anti-CD45 MAb (CA12.10C12) (10, 11, 20 Bi.
Additionally, the longer half-life of 211 At has logistical and, potentially, therapeutic benefits.
211
At is available at our institution by irradiation of a bismuth target with an α-particle beam from a cyclotron. An important consideration for initiating the investigation with 211 At was the fact that recent upgrades on the cyclotron and target station used to produce The use of MAb-ADTM conjugates provided high radiochemical yields (70-80%) through direct labeling of 211 At, and provided high in vivo stability to deastatination.
The biodistribution studies showed that the much higher radiation doses delivered by 211 At depleted the hematopoietic cells and accounted for the differences seen in the spleen weights.
While a large portion of the difference in radiation doses was provided by the fact that there are 9.49 times more 211 At atoms per μCi administered, it appears that another factor of 2x in the dose may be due to the longer half-life of 211 At, permitting more localization of MAb to the spleen prior to decay. Thus, from the tissue radiation dose estimates, 500 μCi of At was more effective at myelosuppression for the same quantity of radioactivity injected than 
